期刊文献+

西格列汀联合二甲双胍与阿卡波糖联合二甲双胍治疗2型糖尿病患者的临床效果比较 被引量:8

下载PDF
导出
摘要 目的探讨西格列汀联合二甲双胍与阿卡波糖联合二甲双胍治疗2型糖尿病患者的临床效果比较。方法100例2型糖尿病患者,随机分为对照组和观察组,每组50例。对照组实施阿卡波糖联合二甲双胍治疗,观察组实施西格列汀联合二甲双胍治疗。观察比较两组治疗效果;治疗前后血糖指标[空腹血糖(FBG)、餐后2 h血糖(2 h PBG)、糖化血红蛋白(HbA1c)]、胰岛素抵抗指数、胰岛B细胞功能水平;2 h PBG、FBG降低到正常值所需时间;胃肠道反应发生情况。结果观察组患者总有效率100.00%高于对照组的78.00%,差异具有统计学意义(P<0.05)。治疗后,两组患者FBG、2 h PBG、HbA1c、胰岛素抵抗指数、胰岛B细胞功能水平均优于治疗前,差异具有统计学意义(P<0.05);观察组患者FBG、2 h PBG、HbA1c、胰岛素抵抗指数分别为(7.34±1.21)mmol/L、(9.18±2.01)mmol/L、(6.22±1.11)%、(2.32±0.12),均低于对照组的(9.77±1.51)mmol/L、(11.56±2.10)mmol/L、(8.10±1.15)%、(2.68±0.24),胰岛B细胞功能(52.19±16.52)%高于对照组的(41.21±12.11)%,差异具有统计学意义(P<0.05)。观察组患者2 h PBG、FBG降低到正常值所需时间分别为(5.78±1.80)、(8.21±1.26)d,均短于对照组的(7.11±2.47)、(10.13±2.67)d,差异具有统计学意义(P<0.05)。对照组出现胃肠道反应1例(2.00%),观察组出现胃肠道反应2例(4.00%),两组胃肠道反应发生率比较差异无统计学意义(P>0.05)。结论西格列汀联合二甲双胍治疗2型糖尿病效果确切,可获得理想效果。
出处 《中国现代药物应用》 2019年第21期179-180,共2页 Chinese Journal of Modern Drug Application
  • 相关文献

二级参考文献64

  • 1中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中华糖尿病杂志增刊,2012,(20):S1-S37.
  • 2International diabetes federation. Global Guideline for Type 2 Diabetes[S]. International Diabetes Federation,2012.
  • 3American Diabetes Association. Standards of medical care in diabetes 2013[J]. Diabetes Care,2013,36(Supplement 1) : 11-60.
  • 4Yang W, Pan CY, Tou C, et al. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus:A randomized controlled trial[J]. Dia- betes Res Clin Pract, 2011,94 (2) : 217-224.
  • 5Pfittzner A, Paz-Pacheco E, Allen E, et al. Initial combi- nation therapy with saxagliptin and mefformin provides sustained glycaemic control and is well tolerated for up to 76 weeks[J]. Diabetes Obes Metab, 2011,13 (6) : 567-576.
  • 6Kadowaki T, Tajima N, Odawara M, et al. Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks[J]. J Diabetes Investig,2013,4(2) : 174-181.
  • 7Pan C,Yang W,Barona JP, et al. Comparison of vildagliptin and acarbose monotherapy in patients with type 2 dia- betes : A 24-week,double-blind,randomized trial[J]. Dia- bet Med, 2008,25 (4) : 435-441.
  • 8Mulherin AJ,Oh AH,Kim H,et al. Mechanisms underly- ing metformin-induced secretion of glucagon-like pep- tide-1 from the intestinal L cell[J]. Endocrinology,2011, 152(12) :4610-4619.
  • 9Raz I,Chen Y,Wu M,et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes[J]. Curt Med Res Opin,2008,4(2):537-550.
  • 10Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 dia- betes inadequately controlled with metformin alone[J]. Diabetes Care, 2006,29(12): 2638-2643.

共引文献64

同被引文献73

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部